Johnson & Johnson eyes biggest drop in over 18 months on weak device sales

By Reuters News

** Shares of Johnson & Johnson JNJ.N fall 6.9% to an over three-month low of $245.48

** Stock set for its steepest one-day pct drop since April 2025, if losses hold

** JNJ's Q3 MedTech sales rise 2.5% to $8.6 bln, but misses analysts' est of $8.71 bln, according to data compiled by LSEG

** Overall, Q3 adj EPS of $2.59 beats est of $2.54, and sales of $25.4 bln beat est of $25.28 bln, as per LSEG data

** "While the results overall are generally inline with expectations, we believe investors will be disappointed in some of the details within the results," says Guggenheim analyst Vamil Divan, noting that the MedTech results were "somewhat disappointing"

** Co lifts its 2026 forecast and now expects about $101.2 bln in reported sales and adjusted EPS of $11.10 at the midpoint, vs prior view of about $101.1 bln and $11.04, respectively

** Analysts, on avg, expect 2026 sales of about $101.3 bln and adjusted EPS of $11.08, according to data compiled by LSEG

** As of last close, JNJ up 27.4% YTD, outperforming the S&P 500 .SPX 11.7% rise

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.